Cruz-Hernández V, León-Tapia S, Cruz-Reyes MÁ, Sosa-López R, Arango-Díaz Á, González-Sánchez E

Language: Spanish
References: 19
Page: 204-209
PDF size: 284.67 Kb.

ABSTRACT

American visceral leishmaniasis clinically manifested by fever, lymphadenopathy, splenomegaly, and sometimes may have anemia, leukopenia and thrombocytopenia, because bone marrow may be involvement as part of the mononuclear phagocytic system. The study of bone marrow is a resource for a rapid, easy and affordable diagnostic of this entity. It also serves to make a differential diagnosis including myeloproliferative and lymphoproliferative diseases. We present three cases of LVA in our hospital; one of them was treated with amphotericin B responded well to healing.

REFERENCES

1. Albrecht H. Redefining AIDS: Towards a modification of the current AIDS case definition. Clin Infect Dis 1997;24:64-74.

2. Kubar J, Marty P, Lelièvre A, et al. Visceral leishmaniosis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of CD4+ T lymphocyte counts. AIDS 1998;12:2147-2153.

3. Gershkovich P, Wasan EK, Sivak O et al. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother 2010;65:535-537.

4. Chappuis F, Sundar S, Hailu A, Ghalib H. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nature Reviews Microbiology, 2007.

5. Córdova C, Albertos N, Andrade F, Canto S. Leishmaniasis: estudio preliminar en una localidad de la zona endémica del estado de Tabasco. Salud Pública Mex 1993;35:345-350.

6. Ingeborg B, Carrada-Figueroa G, Gudiño-Zayas G, González C, Berzunza-Cruz M, Rivas-Sánchez B. Análisis de leishmaniasis en México, consulta de expertos. OPS/OMS, 2005;227- 233.

7. Hernández-Flores JJ, Juan-Aguirre J, Zamora-Chávez A. Leishmaniasis visceral tratada con anfotericina B. Bol Med Hosp Infant 2007;64.

8. Berman JD. Human Leishmaniasis: clinical, diagnostic and chemotherapeutic developments in the last 10 years. Clin Infect Dis 1997;24:684-703.

9. Herwaldt B. Leishmaniasis. Lancet 1999;354:1191-1199.

10. Alvar J, Aparicio P, Aseffa A, Den BM. The Relationship between Leishmaniasis and AIDS: the Second 10 Years. Clinical Microbiology Reviews, 2008.

11. Leishmaniasis, actualización 2007. Organización Panamericana de la Salud.

12. Blanchette J, Racette N, Faure R, Siminovitch KA, et al. Leishmania-induced increases in activation of macrophage SHP-1 tyrosine phosphatase are associated with impaired interferon-G triggered JAK2 activation. Eur J Immunol 1999; 29: 3737-3744.

13. Olivier M. Modulation of host cell intracellular Ca21. Parasitol Today 1996;12:145-150.

14. Arias-Negrete S, Keller K, Chadee K. Proinflammatory cytokines regulate cyclooxygenase-2 mRNA expression in human macrophages. Biochem Biophys Res Comm 1995;208:582- 589.

15. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin Microbiol Rev 1997;10:298-312.

16. Control del Informe de la Secretaría, Organización Mundial de la Salud, marzo 2007.

17. Córdoba-Lanús E, Piñero JE, González AC, et al. Detection of Leishmania braziliensis in Human Paraffin-embedded Tissues from Tucumán, Argentina by Polymerase Chain Reaction. Mem Inst Oswaldo Cruz, 2005.

18. Epidemiología y control de la leishmaniasis en las Américas, por país o territorio. Organización Panamericana de la Salud, Cuaderno técnico 44.

19. Guía para el equipo de salud 5. Dirección de Epidemiología, Ministerio de Salud de la Nación. www.msal.gov.ar